Domain and Merck KGaA partnered to develop metabotropic glutamate receptor subtype 4 positive allosteric modulators to treat Parkinson's disease (PD) and other neurodegenerative diseases

Domain Therapeutics S.A.

France / Private Biopharma

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Merck KGaA

Germany / Mid-Cap Biopharma ($1-$50 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced